Brad Buttimer

Brad Buttimer is an accomplished professional in the biotechnology and pharmaceutical industries with extensive experience in oncology and hematology. Currently serving as a Diagnostic Hematology Specialist for Adaptive Biotechnologies Corp. since April 2021, Buttimer focuses on the clonoSEQ assay for detecting and monitoring minimal residual disease in various blood cancers. Prior to this role, Buttimer held positions at The Janssen Pharmaceutical Companies of Johnson & Johnson as a Senior Oncology Specialist, achieving multiple awards for performance and leadership from 2014 to 2021. Before Janssen, Buttimer excelled as a Senior Oncology Specialist at Amgen and won several regional awards. Early career achievements include successful tenures at Smiths Medical and CCS Medical, where Buttimer received national recognition and awards. Buttimer holds a Bachelor of Science degree in Public Relations from Georgia Southern University.